yes - i read in a report by Bank Credit Analyst ho
Post# of 145613
On the NASH front, the huge number of new obesity drugs now hitting the market will cut the progression of fatty liver disease - great for the population, but will result in fewer patients with NASH.
The bottom line is that the clock is ticking - i really hope we find a new CEO fast, and get out of this holding pattern. i still believe in this drug, but we need a win, and relatively quickly.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)